DSM-Firmenich stock leaps after Q2 results meet expectations

Published 31/07/2025, 09:30
DSM-Firmenich stock leaps after Q2 results meet expectations

Investing.com -- DSM-Firmenich AG stock gained 3.3% after the company reported second quarter adjusted EBITDA of €610 million, matching analyst consensus of €609 million, as organic growth and margin improvement offset temporary vitamin headwinds.

The Dutch-Swiss specialty chemicals company posted sales of €3,236 million for the quarter, slightly below the consensus estimate of €3,239 million but representing a 6% organic growth year-over-year, driven by 2% volume growth and 4% price increases.

DSM-Firmenich’s adjusted EBITDA margins improved significantly, rising 300 basis points compared to the same period last year. The company’s organic growth excluding its animal nutrition business was 3.1%, slightly below consensus expectations of 3.4%.

Looking ahead, DSM-Firmenich updated its full-year 2025 adjusted EBITDA guidance to "around €2.4 billion," a slight adjustment from its previous outlook of "at least" €2.4 billion. The current analyst consensus stands at €2.37 billion. The guidance includes a €150 million temporary impact from vitamins, with €125 million of this effect already recorded in the first half of the year.

The company also noted that the divestment of its animal nutrition business is progressing well and entering its final stages, though no specific timeline was provided for completion of the transaction.

All divisions performed broadly in line with expectations during the quarter, contributing to the positive market reaction despite the slight moderation in full-year guidance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.